After three reviews, the FDA approved flibanserin for hypoactive sexual desire disorder in premenopausal women, concluding that efficacy had been established but requiring a boxed warning, an alcohol contraindication, and a risk evaluation and mitigation strategy.
No takes yet. Share an insight, caveat, or question.
Joffe et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: